Zydus Lifesciences Limited (BOM:532321)

Market Cap	964.27B
Revenue (ttm)	232.42B
Net Income (ttm)	45.26B
Shares Out	n/a
EPS (ttm)	44.97
PE Ratio	21.31
Forward PE	21.17
Dividend	3.00 (0.31%)
Ex-Dividend Date	Jul 26, 2024

Volume	71,264
Average Volume	56,803
Open	947.30
Previous Close	957.00
Day's Range	947.30 - 957.90
52-Week Range	797.05 - 1,323.90
Beta	n/a
RSI	60.13
Earnings Date	Aug 8, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 26,921
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.